Milken Institute Future of Health Summit
December 7 - December 10
The Milken Institute Future of Health Summit convenes the best minds in the world to confront the most significant health challenges by matching human, financial, scientific, and educational resources with innovative and impactful ideas. The Summit will focus on the converging crises of public health, economic insecurity, and social injustice. COVID-19 has exposed weaknesses across our health systems, particularly in the treatment of our most vulnerable communities, where access to affordable and quality health care has never been more vital.
Participants include Kevin Outterson, Executive Director of CARB-X, who will be moderating a session entitled “Are Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives” on Tuesday, December 8th from 12:00pm – 1:00pm EST.
Are Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives: As the COVID-19 pandemic continues, the use of antibiotics in COVID patients is driving antimicrobial resistance (AMR) as patients develop secondary infections. With the exit of all but a few large pharmaceutical companies from developing new antibiotics, small and medium sized enterprises have sought to fill that gap and develop innovative therapies to ensure we have an arsenal of drugs to treat and prevent infections. But as the bankruptcy of numerous small companies in the last year illustrates, times are tough for companies even with a newly approved antibiotic. Recognizing this crisis, a number of large pharmaceutical companies came together to recently launch a $1 Billion USD fund to support antibiotic development. This Antimicrobial Action Fund is a welcome investment and offers the market more time to right itself, but it is clear we need a pull incentive to drive the market. How can we get a pull incentive in place and what can we learn from NICE/NHS’ subscription model pilot in the UK? Is a pull incentive enough to attract new private investment into this space? And how can we develop a truly sustainable market for antibiotics so that drug-resistant infection does not develop into the next pandemic?